Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational, Longitudinal Study to Describe the Outcome, and Outcome Predictors, of Patients With Primary Membranous Nephropathy, and the Nephrotic Syndrome Treated With Rituximab, or Other Monoclonal Antibodies

NCT06242327 is registered in ClinicalTrials.gov with Mario Negri Institute for Pharmacological Research as lead sponsor.

NCT NCT06242327
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06242327 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational, Longitudinal Study to Describe the Outcome, and Outcome Predictors, of Patients With Primary Membranous Nephropathy, and the Nephrotic Syndrome Treated With Rituximab, or Other Monoclonal Antibodies
Lead sponsor
Mario Negri Institute for Pharmacological Research
Phase
Observational
Overall status
Recruiting
Start date
November 29, 2024
Completion date
June 30, 2054
Enrollment
500 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

membranous nephropathy